{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:18:25Z","timestamp":1760300305456},"reference-count":36,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2019,12,25]]},"DOI":"10.1253\/circj.cj-19-0782","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T22:03:36Z","timestamp":1574892216000},"page":"83-90","source":"Crossref","is-referenced-by-count":12,"title":["Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease\u3000\u2015 Propensity Score Matching Analysis \u2015"],"prefix":"10.1253","volume":"84","author":[{"given":"Hyun-Jin","family":"Kim","sequence":"first","affiliation":[{"name":"Cardiovascular Center, Hanyang University Guri Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Ho","family":"Jo","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Hallym University Sacred Heart Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Woo","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Ewha Womans University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Oh","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular and Stroke Imaging Center, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Suk","family":"Ahn","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Uijeongbu St. Mary\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Ju","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Bundang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-Hyung","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Dongtan Sacred Heart Hospital, College of Medicine, Hallym University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics \u2013 2019 update: A report from the American Heart Association. <i>Circulation<\/i> 2019; 139: e56\u2013e528."},{"key":"2","unstructured":"2. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease &amp; end-stage renal disease in the United States. <i>Am J Kidney Dis<\/i> 2012; 59: A7, e1\u2013e420."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bock JS, Gottlieb SS. Cardiorenal syndrome: New perspectives. <i>Circulation<\/i> 2010; 121: 2592\u20132600.","DOI":"10.1161\/CIRCULATIONAHA.109.886473"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lofman I, Szummer K, Dahlstrom U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. <i>Eur J Heart Fail<\/i> 2017; 19: 1606\u20131614.","DOI":"10.1002\/ejhf.821"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. <i>Eur Heart J<\/i> 2014; 35: 455\u2013469.","DOI":"10.1093\/eurheartj\/eht386"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hein AM, Scialla JJ, Edmonston D, Cooper LB, DeVore AD, Mentz RJ. Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. <i>JACC Heart Fail<\/i> 2019; 7: 371\u2013382.","DOI":"10.1016\/j.jchf.2019.02.009"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Curtis BM, Parfrey PS. Congestive heart failure in chronic kidney disease: Disease-specific mechanisms of systolic and diastolic heart failure and management. <i>Cardiol Clin<\/i> 2005; 23: 275\u2013284.","DOI":"10.1016\/j.ccl.2005.04.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, et al. Inflammatory activation: Cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. <i>Heart Fail Rev<\/i> 2012; 17: 177\u2013190.","DOI":"10.1007\/s10741-011-9261-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: \u2018Guyton revisited\u2019. <i>Eur Heart J<\/i> 2005; 26: 11\u201317.","DOI":"10.1093\/eurheartj\/ehi020"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: A systematic integrative review. <i>Biomed Res Int<\/i> 2014; 2014: 937398.","DOI":"10.1155\/2014\/937398"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. <i>JAMA<\/i> 2006; 296: 1377\u20131384.","DOI":"10.1001\/jama.296.11.1377"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). <i>Circulation<\/i> 2002; 106: 920\u2013926.","DOI":"10.1161\/01.CIR.0000029801.86489.50"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. <i>N Engl J Med<\/i> 1991; 325: 303\u2013310.","DOI":"10.1056\/NEJM199108013250502"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial: The Losartan Heart Failure Survival Study ELITE II. <i>Lancet<\/i> 2000; 355: 1582\u20131587.","DOI":"10.1016\/S0140-6736(00)02213-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>N Engl J Med<\/i> 2003; 349: 1893\u20131906.","DOI":"10.1056\/NEJMoa032292"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Edner M, Benson L, Dahlstrom U, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: A prospective propensity score-matched cohort study. <i>Eur Heart J<\/i> 2015; 36: 2318\u20132326.","DOI":"10.1093\/eurheartj\/ehv268"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. <i>Am Heart J<\/i> 2007; 153: 1064\u20131073.","DOI":"10.1016\/j.ahj.2007.03.017"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. <i>Circulation<\/i> 1993; 88: 107\u2013115.","DOI":"10.1161\/01.CIR.88.1.107"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kim HL, Kim MA, Choi DJ, Han S, Jeon ES, Cho MC, et al. Gender Difference in the prognostic value of N-terminal pro-B type natriuretic peptide in patients with heart failure: A report from the Korean Heart Failure Registry (KorHF). <i>Circ J<\/i> 2017; 81: 1329\u20131336.","DOI":"10.1253\/circj.CJ-16-1345"},{"key":"20","unstructured":"20. National Kidney F. K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. <i>Am J Kidney Dis<\/i> 2002; 39: S1\u2013S266."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kim MS, Lee JH, Cho HJ, Cho JY, Choi JO, Hwang KK, et al. KSHF Guidelines for the Management of Acute Heart Failure. Part III: Specific management of acute heart failure according to the etiology and co-morbidity. <i>Korean Circ J<\/i> 2019; 49: 46\u201368.","DOI":"10.4070\/kcj.2018.0351"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. <i>J Card Fail<\/i> 2007; 13: 422\u2013430.","DOI":"10.1016\/j.cardfail.2007.03.011"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. <i>J Am Coll Cardiol<\/i> 2006; 47: 1987\u20131996.","DOI":"10.1016\/j.jacc.2005.11.084"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Shiba N, Shimokawa H. Chronic kidney disease and heart failure: Bidirectional close link and common therapeutic goal. <i>J Cardiol<\/i> 2011; 57: 8\u201317.","DOI":"10.1016\/j.jjcc.2010.09.004"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: The Cardiovascular Research Network PRESERVE Study. <i>Circ Cardiovasc Qual Outcomes<\/i> 2013; 6: 333\u2013342.","DOI":"10.1161\/CIRCOUTCOMES.113.000221"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Jugdutt BI. Expanding saga of the renin-angiotensin system: The angiotensin II counter-regulatory AT2 receptor pathway. <i>Circulation<\/i> 2015; 131: 1380\u20131383.","DOI":"10.1161\/CIRCULATIONAHA.115.016328"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kalra D, Sivasubramanian N, Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. <i>Circulation<\/i> 2002; 105: 2198\u20132205.","DOI":"10.1161\/01.CIR.0000015603.84788.47"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. <i>Kidney Int Suppl<\/i> 2002; (82): S12\u2013S22.","DOI":"10.1046\/j.1523-1755.62.s82.4.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. <i>J Am Coll Cardiol<\/i> 2000; 35: 714\u2013721.","DOI":"10.1016\/S0735-1097(99)00594-X"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Neri Serneri GG, Boddi M, Modesti PA, Coppo M, Cecioni I, Toscano T, et al. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. <i>Circ Res<\/i> 2004; 94: 1630\u20131637.","DOI":"10.1161\/01.RES.0000130944.49657.b8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. <i>J Am Coll Cardiol<\/i> 2003; 42: 905\u2013910.","DOI":"10.1016\/S0735-1097(03)00846-5"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Lauten WB, Khan QA, Rajagopalan S, Lerakis S, Rahman ST, Parthasarathy S, et al. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. <i>Am J Cardiol<\/i> 2003; 91: 1116\u20131119.","DOI":"10.1016\/S0002-9149(03)00161-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Damman K, Tang WH, Felker GM, Lassus J, Zannad F, Krum H, et al. Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: Practical considerations from published data. <i>J Am Coll Cardiol<\/i> 2014; 63: 853\u2013871.","DOI":"10.1016\/j.jacc.2013.11.031"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Ahmed A, Love TE, Sui X, Rich MW. Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: A propensity score analysis. <i>J Card Fail<\/i> 2006; 12: 499\u2013506.","DOI":"10.1016\/j.cardfail.2006.05.008"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. <i>Nat Rev Nephrol<\/i> 2013; 9: 459\u2013469.","DOI":"10.1038\/nrneph.2013.110"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Lu R, Zhang Y, Zhu X, Fan Z, Zhu S, Cui M, et al. Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: A systematic review and meta-analysis. <i>Int Urol Nephrol<\/i> 2016; 48: 1499\u20131509.","DOI":"10.1007\/s11255-016-1319-7"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/1\/84_CJ-19-0782\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T03:22:14Z","timestamp":1579922534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/1\/84_CJ-19-0782\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-19-0782","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,25]]}}}